Frontlight ResearchEarly access
Haemophilia trials in Canada
12 of 19 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 4Taking peopleEfanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
- Where
- Calgary, Hamilton, St. John's
- Age
- 12 years and over
- People
- 35 worldwide
- Run by
- Sanofi
See details and how to joinNCT06941870 - Phase 1/2Taking peopleA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
- Where
- Hamilton, Vancouver
- Age
- 2 years to 59 years
- People
- 60 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05987449 · EU 2023-503906-35-00 - Phase 3Taking peopleA Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
- Where
- London
- Age
- 12 years and over
- People
- 360 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07416604 · EU 2025-522435-33-00 - Phase 3Not yet taking people in CanadaA Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A
- Where
- Hamilton, Toronto, Vancouver
- Age
- 18 years and over
- People
- 84 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07830732 · EU 2026-525529-19-00 - Phase 3Taking peopleA Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
- Where
- Hamilton, Montreal, Toronto
- Age
- 1 year to 11 years
- People
- 85 worldwide
- Run by
- Sanofi
See details and how to joinNCT07285460 · EU 2025-521858-42-00 - Phase 3Taking peopleOpen-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- Where
- Edmonton, Hamilton
- Age
- 1 year to 74 years
- People
- 245 worldwide
- Run by
- Pfizer
See details and how to joinNCT05145127 · EU 2022-500470-33-00 - Phase 1/2Taking peopleA Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
- Where
- Edmonton, Hamilton, Montreal
- Age
- 2 years and over
- People
- 130 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06379789 · EU 2023-507260-40-00 - Phase 3Active, not recruitingA Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
- Where
- Edmonton, Hamilton
- Age
- 1 year to 17 years
- People
- 100 worldwide
- Run by
- Pfizer
See details and how to joinNCT05611801 · EU 2022-500495-65-00 - No phaseEnrolling by invitation3D Ultrasound in Hemophilic Ankles
- Where
- Toronto
- Age
- 5 years to 18 years
- People
- 11
- Run by
- The Hospital for Sick Children
See details and how to joinNCT07452575 - Phase 3Taking peopleSafety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
- Where
- Toronto
- Age
- 18 years and over
- People
- 173 worldwide
- Run by
- Pfizer
See details and how to joinNCT05568719 - Phase 3Taking peopleEfficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
- Where
- Hamilton
- Age
- 18 years and over
- People
- 35 worldwide
- Run by
- CSL Behring
See details and how to joinNCT06003387 · EU 2023-509590-23-00 - Phase 1Taking peopleA Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
- Where
- Hamilton
- Age
- 18 years to 60 years
- People
- 31 worldwide
- Run by
- Equilibra Bioscience LLC
See details and how to joinNCT06349473